Zai Lab Ltd reports results for the quarter ended June 30 - Earnings Summary

• Zai Lab Ltd 9688 reported a quarterly adjusted loss of 40 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -80 cents. The mean expectation of six analysts for the quarter was for a loss of 41 cents per share. Wall Street expected results to range from -56 cents to -35 cents per share.

• Revenue rose 9.4% to $109.98 million from a year ago; analysts expected $125.01 million.

• Zai Lab Ltd's reported EPS for the quarter was a loss of 40 cents​.

• The company reported a quarterly loss of $40.73 million.

• Zai Lab Ltd shares had risen by 10.7% this quarter and gained 47.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 5.8% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Zai Lab Ltd is $55.00, about 29.6% above its last closing price of $38.72

This summary was machine generated from LSEG data August 7 at 02:55 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)